take off after the AGM, page-69

Hi Geffa. Yes to both happily. Expectations of the past grants and incentives will be paid to BD1 and competition was discussed and in term of not as close and most importantly it was stated we are likely to be first to market. That is clearly significant and was stated as Significant". Long day yesterday so my brain and recall was a bit fuzzy at midnight last night sorry

Your other post "This will be a billion company in two years. " is interesting. The Market potential for our products page 7 is "$6574m" another company I watch is Biogen Inc. (BIIB) market cap is 48 billion. total revenues 2018 10,886,000 (usd) (Item 6 page 51)

Not suggesting BD1 will be making the amounts indicated on the AGM report page 7 or even my own rough maths on US, European and our own tiny market here in Australia which have me smiling.

Unlike Biogen which has a pipeline of drugs under development which each take 10ish years and roughly 600million to have a very remote chance of getting to a commercial product for all of the nifty products they are trying to develop; Each of the three test we have and later more to be added all hinged on the first Ovarian test assay getting to the LDT due at or before 2022, The confidence of getting to the LDT and later IVD was very strong. The Bio-banking of bloods for testing makes the whole process repeatable for each subsequent test far more rapidly. The Science, methods and the new staff all make it clear being overweight in a biotech which is normally a no no makes a lot of sense with most risk already removed. Replication of the lab test results with the LDT and IVD seems assured. Its not no risk but a low risk with the very strong potential for multi-bag returns/reward for holders.

It might be in other ASX releases but Prostate and Bowel cancer were mentioned yesterday as strong candidates for addition to our portfolio once the mad rush and ramp up to get the LDT ready for market or even earlier. Did I mention how much I love Dr Irmgard Irminger-Finger